In patients with follicular lymphoma being treated in the third-line setting or later, liso-cel therapy is associated with durable responses.

Treatment with rituximab plus epcoritamab has achieved rapid and deep responses in follicular lymphoma patients with a high tumor burden.

Targeted immunotherapy significantly improved responses and prolonged survival in newly-diagnosed Ph+ ALL compared with chemotherapy.

KRd significantly prolonged progression-free survival and improved the MRD negativity rate compared to VRd in newly diagnosed multiple myeloma.

The Isa-VRd quadruplet regimen induced sustained MRD negativity and a strong rate complete response or better in patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

In patients with advanced-stage classic Hodgkin lymphoma, a PFS benefit was seen at 3 years’ follow-up with N-AVD compared to BV-AVD.

R-CHOP plus ibrutinib, followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC DLBCL.

Standard-risk rel/ref multiple myeloma patients with benefit from earlier treatment with cilta-cel, rather than waiting for later lines of therapy.

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.

Investigators sought to examine the connection between a diagnosis of cancer within 12 months following a diagnosis of hiccups ...

Perioperative chemotherapy is recommended for patients with cT2-4 and/or N+ resectable gastric cancer, preferably 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT).